Bone Diseases, Metabolic  >>  Isentress (raltegravir)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Isentress (raltegravir) / Merck (MSD)
TROP, NCT00939874: Switch From Tenofovir to Raltegravir for Low Bone Mineral Density

Completed
4
52
RoW
Raltegravir, Isentress, MK-0518
St Vincent's Hospital, Sidney, Merck Sharp & Dohme LLC, Holdsworth House Medical Practice, The Alfred
HIV, Osteopenia, Osteoporosis, HIV Infections
06/12
04/14
RALBAT, NCT01902186 / 2013-002349-12: Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir

Terminated
4
4
Europe
raltegravir and atazanavir and ritonavir, Isentress (raltegravir), Reyataz (atazanavir), Norvir (ritonavir), tenofovir/emtricitabine and atazanavir and ritonavir, tenofovir/emtricitabine (Truvada), atazanavir (Reyataz), ritonavir (norvir)
Giovanni Di Perri, University of Turin, Italy, University of Milan
HIV Infection, Osteopenia
12/16
12/16

Download Options